Table 3 Parasitological responses by study
Site | Year | Drug | Enrolled n | Day 3 Pos. n (%) | Non-PCR corrected | PCR corrected | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Excl./loss | LPF | ACPR n (%) | Excl./loss | LPF | ACPR n (%) | KM cure rate % (95% CI) | |||||
Muse | 2011–12 | AL | 55 | 4 (7.3) | 3 | 0 | 52 (100) | 3 | 0 | 52 (100) | 100 (n/a) |
Muse | 2011–12 | AS + MQ | 45 | 1 (2.2) | 1 | 0 | 44 (100) | 1 | 0 | 44 (100) | 100 (n/a) |
Tamu | 2012 | AL | 74 | 4 (5.4) | 2 | 2 | 70 (97.2) | 2 | 2 | 70 (97.2) | 97.3 (89.6–99.3) |
Tamu | 2012 | AS + MQ | 74 | 0 (0) | 4 | 1 | 69 (98.6) | 4 | 1 | 69 (98.6) | 98.6 (90.3–99.8) |
Tabeikkyin | 2014 | AL | 75 | 0 (0) | 5 | 2 | 68 (97.1) | 7 | 0 | 68 (100) | 100 (n/a) |
Tabeikkyin | 2014 | DP | 72 | 0 (0) | 2 | 0 | 70 (100) | 2 | 0 | 70 (100) | 100 (n/a) |
Tamu | 2014 | DP | 75 | 0 (0) | 3 | 2 | 70 (97.2) | 5 | 0 | 70 (100) | 100 (n/a) |